The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy

Cancer Journal

Volumn 10, Issue 5, 2004, Pages 301-306

  Sherertz, Tracy ^a,b   Wallner, Kent ^a,b,c,e,g   Merrick, Gregory ^a,f   Cavanagh, William ^a,b   Butler, Wayne ^a,f   Reed, Daniel ^a,c   True, Lawrence ^a,d  

^a Puget Sound Health Care System ^*

^b Puget Sound Health Care System   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f WHEELING HOSPITAL   (United States)

^g DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Brachytherapy; Gleason score; Prostatic carcinoma

Indexed keywords

PALLADIUM 103; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PALLADIUM; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CONTROL; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; IMPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; SCORING SYSTEM; SEMINAL VESICLE; BIOPSY; BLOOD; BONE TUMOR; BRACHYTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MALE; METASTASIS; METHODOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BONE NEOPLASMS; BRACHYTHERAPY; HUMANS; MALE; NEOPLASM STAGING; PALLADIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; TREATMENT OUTCOME;

EID: 16644394227     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200409000-00007     Document Type: Article

References (19)

1. Gleason D. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-279.
2. Martinez A, Gustafson G, Gonzales J et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316-327.
3. Roach M, Meehan S, Kroll S et al. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol 1996;156:1719-1723.
4. Horwitz E, Winter K, Hanks G et al. Subset analysis of RTOG-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:947-956.
5. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prost carcinoma with selective delayed intervention based on prostate specific antigen, histologic and/or clinical progression. J Urol 2002;167:1664-1669.
6. Wise A, Stamey TA, Mcneal J et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-269.
7. Do T, Parker R, Smith R et al. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001;57:1121-1127.
8. Wallner K, Merrick G, Butler W et al. 20 Gy versus 44 Gy supplemental beam radiation combined with Pd-103 prostate brachytherapy: early results from a prospective randomized multicenter trial. 2005; submitted for publication.
9. Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endo/Hypertherm 1987;3:131-139.
10. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol 2000;6:78-84.
11. Badiozamani KR, Wallner KE, Cavanagh W et al. Comparability of CT-based and TRUS-based prostate volumes. Int J Radiat Oncol Biol Phys 1999;43:375-378.
12. Schwartz D, Billingsley K, Wallner K. Follow-up care for cancer: making the benefits equal the cost. Oncology 2000;14:1493-1505.
13. Tralins K, Wallner K. Follow-up costs after external beam irradiation for low risk prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:323-326.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974;111:58-64.
16. Chism D, Hanlon A, Troncoso P et al. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 2003;56:1241-1247.
17. Pan C-C, Potter S, Partin A et al. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens. Am J Surg Pathol 2000;24:563-569.
18. Pound CR, Partin AW, Epstein JI et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am 1997;24:395-406.
19. Dattoli M, Wallner K, True L et al. Long-term outcomes following EBRT + Pd-103 for higher risk prostatic carcinoma: influence of prostatic acid phosphatase. Cancer 2003;97:979-983.